Journal Article (Review Article)

DZNE-2026-00134

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.

Koeglsperger, T. (First author)DZNE* ; Berberovic, E. ; Dresel, C. ; Haferkamp, S. ; Kassubek, J.Extern* ; Müller, R. ; Oehlwein, C. ; Paus, S. ; Urban, P. P.

2026
Springer Wien [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1007/s00702-025-02911-5

Abstract: Traditional advanced therapies in Parkinson's disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), levodopa-carbidopa entacapone intestinal gel (LECIG), or deep brain stimulation (DBS) have played a central role in managing therapy-related complications. Recently, continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) has emerged as a novel therapeutic option. This manuscript provides insights from one year of real-world experience with CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for advanced PD. Our discussion centers on key considerations for patient selection, exploring which individuals may benefit more from CSFLI compared to other device-aided therapies. We highlight CSFLI's advantages in flexibility and ease of use but also consider limitations, particularly its side effects, such as skin-related issues. Recommendations are presented on how to prevent and manage these adverse effects to maximize patient compliance and therapeutic success. Additionally, the paper examines strategies for optimizing concurrent oral medications when combined with CSFLI, providing guidance on balancing pump infusion with necessary adjunctive oral treatments.

Keyword(s): Humans (MeSH) ; Parkinson Disease: drug therapy (MeSH) ; Antiparkinson Agents: administration & dosage (MeSH) ; Antiparkinson Agents: adverse effects (MeSH) ; Levodopa: administration & dosage (MeSH) ; Levodopa: adverse effects (MeSH) ; Carbidopa: administration & dosage (MeSH) ; Carbidopa: adverse effects (MeSH) ; Drug Combinations (MeSH) ; Infusions, Subcutaneous (MeSH) ; Advanced Treatment ; Foslevodopa/Foscarbidopa ; Motor Fluctuations ; Parkinson’s disease ; Antiparkinson Agents ; Levodopa ; Carbidopa ; Drug Combinations ; carbidopa, levodopa drug combination

---

Contributing Institute(s):

1. Clinical Research (Munich) (Clinical Research (Munich))

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Springer ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---